At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 29 enrolled
Drug / intervention
sitagliptin phosphatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise
In Brief
A Phase 4 clinical trial evaluating sitagliptin phosphate for Diabetes Mellitus. Completed, enrolled 29 participants.
Detailed Summary
After 24 weeks of treatment evaluate the efficacy and security.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
Primary CompletionJul 2008
First PostedJan 2009
TodayJul 2026
First PostedJan 30, 2009
Enrollment StartFeb 14, 2007
Primary CompletionJul 11, 2008
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.4 years ago
Interventions
sitagliptin phosphatedrug
Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets